AVCN.TO - Avicanna Inc.

Toronto - Toronto Delayed Price. Currency in CAD
2.0600
+0.0600 (+3.00%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close2.0000
Open2.0000
Bid2.0500 x N/A
Ask2.0700 x N/A
Day's Range1.9900 - 2.0800
52 Week Range1.2300 - 7.4000
Volume74,212
Avg. Volume57,464
Market Cap47.622M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.9690
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Avicanna Ranks Highest Amongst Global Cannabis Companies in the SAM Corporate Sustainability Assessment (CSA)
    CNW Group

    Avicanna Ranks Highest Amongst Global Cannabis Companies in the SAM Corporate Sustainability Assessment (CSA)

    TORONTO , Feb. 6, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has been rated the highest amongst global cannabis companies participating in the SAM Corporate Sustainability Assessment (CSA). The SAM Corporate Sustainability Assessment (CSA), established by RobecoSAM, is now issued by S&P Global. The 2020 Sustainability Yearbook that was published on January 30th by S&P Global, showcases the sustainability performance of some of the world's largest companies.

  • Avicanna Closes First Tranche of Private Placement
    CNW Group

    Avicanna Closes First Tranche of Private Placement

    TORONTO , Jan. 24, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (FSE:0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has closed the first tranche of an up to CAD$9,000,000 non-brokered private placement (the "Offering"). Under the first tranche of the Offering, the Company has issued an aggregate of 822,721 Units (the "Units") at a price of CAD$2.50 per Unit, for aggregate gross proceeds of approximately CAD$2.06 million . The Company has also received additional subscription agreements for an additional CAD$4 million , which it expects to close on in one or more further tranches on the same terms.

  • Avicanna Announces Appointment of Benjamin Leavenworth as Independent Director
    CNW Group

    Avicanna Announces Appointment of Benjamin Leavenworth as Independent Director

    TORONTO , Jan. 21, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce the appointment of Benjamin Leavenworth to the Company's board of directors, effective immediately. Mr. Leavenworth has more than 20 years' experience in international business, with a focus on Latin America .

  • Avicanna Announces the Successful Completion of its Clinical Study Evaluating the Effect of an Emollient Cream Containing 0.5% Cannabidiol on Skin Hydration
    CNW Group

    Avicanna Announces the Successful Completion of its Clinical Study Evaluating the Effect of an Emollient Cream Containing 0.5% Cannabidiol on Skin Hydration

    TORONTO , Jan. 13, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced today its results from its first cosmetic clinical study, an open-label, randomized, passive-control study examining the impact of its Pura Earth™ topical cream containing 0.5% cannabidiol and 1% hemp oil on skin hydration. The investments that we've made in the research and development of the Pura Earth products is validated by these positive clinical results and further elevates the brand in the CBD derma-cosmetics market.

  • Avicanna Announces Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc., to Distribute Avicanna's Advanced and Evidence-based Medical Cannabis and Derma-Cosmetic Products Across Canada
    CNW Group

    Avicanna Announces Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc., to Distribute Avicanna's Advanced and Evidence-based Medical Cannabis and Derma-Cosmetic Products Across Canada

    TORONTO , Jan. 10, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced today that Medical Cannabis by Shoppers will be the exclusive Canadian distributor of the Rho PhytoTM medical cannabis and Pura EarthTM CBD derma-cosmetic product lines. Medical license holders in Canada will be able to purchase a consistent supply of Avicanna's advanced and evidence-based products starting in early-2020, including the Rho Phyto line, which includes sublingual sprays, oil drops, gels, creams, tablets and capsules.

  • Benzinga

    A Look At Avicanna's $5M Credit Facility And The Cannabis Company's Busy Year

    Avicanna Inc (OTC: AVCNF) (TSE: AVCN) announced Friday that it has entered into a credit facility with Inmobiliaria Bondue S.A.S. Avicanna can borrow up to $5 million per the agreement. Advances produced under the credit facility will carry interest at a rate of 8% per year. The facility is unsecured and is repayable upon default by Avicanna or Bondue’s demand.

  • Avicanna to Host Key Opinion Leader Meeting on the Use of Cannabinoids for the Treatment of Pain and Epilepsy
    CNW Group

    Avicanna to Host Key Opinion Leader Meeting on the Use of Cannabinoids for the Treatment of Pain and Epilepsy

    TORONTO , Dec. 6, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, today announced that it will host a Key Opinion Leader (KOL) meeting on the use of cannabinoids for the treatment of pain and epilepsy on December 12, 2019 in New York City . The event will feature a presentation by KOLs Hance Clarke, MD, PhD., University Health Network - Toronto General Hospital, and Amza Ali , MD, FRCP, MBA, Chief Medical Officer, Avicanna Inc., who will discuss how the use of cannabinoids can help to treat patients with severe pain and epilepsy.

  • Avicanna Receives DTC Eligibility for Common Shares on OTCQX
    CNW Group

    Avicanna Receives DTC Eligibility for Common Shares on OTCQX

    TORONTO , Dec. 5, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (AVCN.TO) (AVCNF) (0NN.F), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has obtained eligibility with the Depository Trust Company ("DTC") for its common shares listed in the United States on the OTCQX® Best Market.

  • Avicanna to Supply UK Market with Cannabis-Based Medicinal Products Through Distribution Agreement with the LYPHE Group
    CNW Group

    Avicanna to Supply UK Market with Cannabis-Based Medicinal Products Through Distribution Agreement with the LYPHE Group

    TORONTO , Dec. 3, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into an importation and distribution agreement (the "Agreement") with Astral Health Ltd. ("Astral"), the operating subsidiary of the LYPHE Group Ltd ("LYPHE Group" or "LYPHE") to supply its cannabis-based medicinal products ("CBMPs") to patients in the United Kingdom under the MHRA 'specials' programme.

  • Avicanna's Rho Phyto Branded Products to be Available in California
    CNW Group

    Avicanna's Rho Phyto Branded Products to be Available in California

    TORONTO , Dec. 1, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) today announces that LC2019, Inc. ("LC2019"), the entity that holds a license to Avicanna's intellectual property in the United States , has advised Avicanna that it has entered into an agreement (the "License Agreement") with a subsidiary of Kings Garden Inc. ("Kings Garden"), a California based company, manufacturing the Kings Garden brand, with extensive experience in the cultivation, processing and manufacturing of high-end cannabis products, pursuant to which LC2019 will sub-license Avicanna's Rho PhytoTM brand and proprietary formulations (collectively, the "Rho Products") to Kings Garden.

  • Avicanna Announces Option to Purchase Newly Formed US Cannabis Operator
    CNW Group

    Avicanna Announces Option to Purchase Newly Formed US Cannabis Operator

    TORONTO , Nov. 26, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has entered into a license agreement (the "License Agreement") with LC2019, Inc. ("LC2019") pursuant to which the Company has agreed to license certain proprietary formulations and brand elements to LC2019 for commercialization in the United States. As consideration for entering into the License Agreement, LC2019 and its shareholders have entered into a definitive option agreement (the "Option Agreement") that grants Avicanna the option (the "Option") to acquire 100 percent of the issued and outstanding shares of LC2019, with such Option to be exercisable in the event that cannabis cultivation, processing, distribution and possession‎ becomes federally legal in the United States (the "Triggering Event").

  • Avicanna Reports Third Quarter 2019 Financial Results
    CNW Group

    Avicanna Reports Third Quarter 2019 Financial Results

    During this time, we have initiated several revenue streams through our various product lines, which we expect to drive the Company's future growth. This first batch included a total of approximately 28,000 units of Pura Earth product manufactured using approximately 28 kilograms of the Company's purified cannabidiol ("CBD"). Clinical trials for Avicanna's branded derma-cosmetic line, Pura Earth, with the Centro de Atencion e Investigacion Medica CAIMED S.A.S., commenced during the quarter.

  • Avicanna Announces Voluntary Lock-Up Agreements for Key Insiders and Separation of CEO and Chairman Roles
    CNW Group

    Avicanna Announces Voluntary Lock-Up Agreements for Key Insiders and Separation of CEO and Chairman Roles

    TORONTO , Oct. 29, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, today announces that its executive officers and directors have entered into voluntary lock-up agreements to extend the term of their lock-up periods, affecting approximately 7.7 million shares. The Company also announces that Kyle Langstaff has stepped down as Vice President (Operations) and has concurrently entered into a lock-up agreement to restrict the disposition of his common shares. In addition, the Company's board of directors has separated the roles of Chairman and Chief Executive Officer.

  • Avicanna (TSX: AVCN) Completes First Commercial Exports of CBD to South Africa and the United Kingdom
    CNW Group

    Avicanna (TSX: AVCN) Completes First Commercial Exports of CBD to South Africa and the United Kingdom

    TORONTO , Oct. 24, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN)(OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of cannabinoid-based products, is pleased to announce that Santa Marta Golden Hemp S.A.S. ("SMGH"), its majority owned subsidiary, has completed commercial exports of its Aureus™ brand of CBD-based products to South Africa and the United Kingdom (collectively, the "Jurisdictions"). The Aureus brand of products include an organic and sustainable line of plant-derived active pharmaceutical ingredients ("APIs") and bulk CBD formulations developed by Avicanna in collaboration with SMGH and Sativa Nativa S.A.S. ("Sativa Nativa"), which is also a majority owned subsidiary of Avicanna. These initial sales included the export of CBD isolate and 4% bulk formulation for CBD oil sublingual sprays.

  • Avicanna Announces Retail Launch of Pura Earth Derma-Cosmetics with Initial Roll-Out in Colombia
    CNW Group

    Avicanna Announces Retail Launch of Pura Earth Derma-Cosmetics with Initial Roll-Out in Colombia

    TORONTO , Oct. 21, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce the retail launch of its Pura Earth™ derma-cosmetics line of CBD products, which are now available at approximately 59 high-end retail locations throughout Colombia , including Blind prestige beauty shops and Cromantic professional beauty markets. Avicanna's Anti-Aging Treatment, Anti-Aging Serum, Clear Skin Treatment and Intensive Skin Conditioning Treatment, which are the first four of the nine Pura Earth product lines, are currently available at retail. Additionally the Pura Earth line will be offered on e-commerce platforms, including Percos, Cormantic, and Blind, as well as Avicanna's own platform, which is currently dedicated to Pura Earth.

  • Avicanna (TSX: AVCN) Announces Receipt of the First Colombian USDA Organic Certification for its Hemp Cultivation and Registration of 15 Additional Genetics
    CNW Group

    Avicanna (TSX: AVCN) Announces Receipt of the First Colombian USDA Organic Certification for its Hemp Cultivation and Registration of 15 Additional Genetics

    TORONTO , Oct. 18, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that Santa Marta Golden Hemp S.A.S. ("SMGH"), a majority owned subsidiary of the Company, has obtained a United States Department of Agriculture ("USDA") National Organic Program ("NOP") certification from Control Union Certifications, for its hemp cultivar, and has obtained registration for an additional 15 genetic strains of cannabis.

  • Avicanna Commences Trading on the OTCQX Market in the United States
    CNW Group

    Avicanna Commences Trading on the OTCQX Market in the United States

    TORONTO , Oct. 15, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of cannabinoid-based products, is pleased to announce that its common shares will commence trading today on the OTCQX® Best Market in the United States under the symbol "AVCNF". The OTCQX Best Market provides added service, value and convenience to U.S. investors, brokers and institutions seeking to trade Avicanna shares. OTCQX is OTC Markets Group's premier market for established, investor-focused U.S. and international companies.

  • Is Avicanna (TSE:AVCN) Using Debt In A Risky Way?
    Simply Wall St.

    Is Avicanna (TSE:AVCN) Using Debt In A Risky Way?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

  • Avicanna (TSX: AVCN) Announces First Commercial Sale of the Pura Earth Derma-Cosmetics line of CBD Products
    CNW Group

    Avicanna (TSX: AVCN) Announces First Commercial Sale of the Pura Earth Derma-Cosmetics line of CBD Products

    TORONTO , Oct. 2, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce the first completed commercial sale of its Pura Earth™ derma-cosmetics line of CBD products. The sale was completed through Avicanna's wholly owned subsidiary, Avicanna LATAM S.A.S., to Percos S.A. ("Percos"), Avicanna's exclusive distributor of Pura Earth™ derma-cosmetics products in Colombia .

  • Avicanna (TSX: AVCN) to Open its Next Phase Extraction Facility in Colombia's Free Trade Zone
    CNW Group

    Avicanna (TSX: AVCN) to Open its Next Phase Extraction Facility in Colombia's Free Trade Zone

    TORONTO , Sept. 30, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce plans to build a new industrial scale 11,000 sq. ft ( 1,000 square meter) cannabinoid extraction and final product manufacturing facility in a Colombian free trade zone near Santa Marta. This new facility is expected to provide for significant tax advantages and represents the third phase of the Company's extraction strategy, building on its existing subsidiaries' extraction and manufacturing operations in Colombia with current aggregate annual capacity of dried flower – post extraction and isolation – of approximately 100,000 kilograms.

  • Avicanna (TSX: AVCN) Aras Azadian, CEO & Co-Founder to speak at the 12th Annual International Natural & Organic Cosmetics Conference About Organic CBD Skin Care and Pura Earth™ in Berlin, Germany
    CNW Group

    Avicanna (TSX: AVCN) Aras Azadian, CEO & Co-Founder to speak at the 12th Annual International Natural & Organic Cosmetics Conference About Organic CBD Skin Care and Pura Earth™ in Berlin, Germany

    TORONTO , Sept. 23, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company")(TSX: AVCN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that its CEO and Co-Founder Aras Azadian will be a highlighted speaker on the global organic cosmetics industry and the use of CBD in cosmetic products and specifically Avicanna's organic CBD cosmetic line Pura Earth at a leading industry conference in Berlin, Germany .

  • Avicanna (TSX: AVCN) Enters an Exclusive Research Agreement with the University of Guelph for Proprietary Cannabinoid-based Products and Formulations to Treat Psychiatric Disorders
    CNW Group

    Avicanna (TSX: AVCN) Enters an Exclusive Research Agreement with the University of Guelph for Proprietary Cannabinoid-based Products and Formulations to Treat Psychiatric Disorders

    TORONTO , Sept. 13, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it will further the research and development and pre-clinical analysis of its proprietary prescription and over-the-counter ("OTC") cannabinoid products and formulations through an exclusive research agreement with the University of Guelph in Canada for a project to be performed by Dr. Jibran Khokhar , Assistant Professor at the University of Guelph , Ontario Veterinary College, Department of Biomedical Sciences, as principal investigator.

  • Market Exclusive

    Avicanna Working with University of Toronto and University of Guelph on Cannabinoid Research

    Avicanna (TSX: AVCN) (OTCMKTS:AVCIF), a biopharmaceutical company focused on plant-derived cannabinoid-based products, said it has expanded its research and collaboration agreement with Dr. Christine Allen's research group at the University of Toronto. Dr. Allen has stepped down as Avicanna's chief scientific officer and has joined the University of Toronto. However, she will increase her involvement […]The post Avicanna Working with University of Toronto and University of Guelph on Cannabinoid Research appeared first on Market Exclusive.

  • Avicanna (TSX: AVCN) Further Strengthens its Position as a Canadian Leader in Cannabinoid Based Research and Development with Expansion of University of Toronto Collaboration and Execution of University of Guelph Research Agreement
    CNW Group

    Avicanna (TSX: AVCN) Further Strengthens its Position as a Canadian Leader in Cannabinoid Based Research and Development with Expansion of University of Toronto Collaboration and Execution of University of Guelph Research Agreement

    TORONTO , Aug. 30, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has expanded the scope and duration of its research and collaboration agreement with Dr. Christine Allen's research group at the University of Toronto . Additionally, Dr. Allen has stepped down as Avicanna's Chief Scientific Officer, having accepted a prominent role with the University of Toronto , however, Dr. Allen will increase her involvement in Avicanna's pharmaceutical development and optimization through the expanded collaboration between Avicanna and Dr. Allen's research group.

  • Avicanna (TSX: AVCN) Completes its First Exportation of Cannabinoids from Colombia to Canada for Scientific Purposes
    CNW Group

    Avicanna (TSX: AVCN) Completes its First Exportation of Cannabinoids from Colombia to Canada for Scientific Purposes

    TORONTO , Aug. 23, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that its subsidiary, Santa Marta Golden Hemp S.A.S. ("SMGH"), has completed its first export of purified cannabidiol ("CBD") from Colombia to Canada for research and development purposes. Aras Azadian , Chief Executive Officer of Avicanna commented "We are thrilled to complete our first export and proud to be doing so into Canada . Health Canada issued three authorizations to SMGH on June 28, 2019 to allow for the import of CBD isolates and cannabis resin into Canada from Colombia for scientific purposes.